Citation Tools
PDFTherapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease